Accessibility StatementSkip Navigation NORTH CHICAGO, Ill., Dec. 1, 2025 /PRNewswire/ --Â AbbVie (NYSE: ABBV) today announced primary results from the pivotal Phase 3 ECLIPSE study, evaluating the safety, efficacy and tolerability of atogepant (60 mg) versus placebo for the acute treatment of migraine in adults (with or without aura). The study met its primary and key secondary endpoints, with atogepant demonstrating superiority in pain freedom and freedom from most bothersome migraine symptom (MBS) two hou ...

Core Viewpoint - The article highlights three dividend-paying stocks—AbbVie, Home Depot, and ExxonMobil—that have consistently raised their dividends for over a decade, offering yields significantly higher than the S&P 500 average, making them attractive long-term investments. AbbVie - AbbVie currently offers a dividend yield of approximately 2.9%, which is more than double the S&P 500 average of 1.2% [3] - The company has a history of over 50 consecutive years of dividend increases, qualifying it as a Dividend King [3][4] - AbbVie recently raised its dividend by 5.5%, and since its spin-off from Abbott Laboratories, it has increased quarterly dividends by over 330% [4] - For the first nine months of the year, AbbVie reported an 8% increase in sales, totaling $44.5 billion, with Skyrizi and Rinvoq generating $18.5 billion, surpassing Humira's current quarterly sales of $3.3 billion [6][7] Home Depot - Home Depot has raised its dividend for 16 consecutive years, with a more than 50% increase since 2020, currently yielding 2.7% [8] - Despite facing challenges due to decreased discretionary spending, the company anticipates a 3% sales growth for the current fiscal year [9] - Home Depot's shares have declined by 13% this year, but the company is expected to recover in the long term due to its strong position in the home repair market [12] ExxonMobil - ExxonMobil offers the highest yield among the three at 3.5%, with a history of 43 consecutive years of annual dividend growth at an average rate of 5.8% [13][14] - The company has faced earnings volatility, with a decline of $3.7 billion to $22.3 billion this year, but it maintains strong financial health, with earnings per share of $5.16 exceeding its annual dividend payout of $4.12 [14][16] - ExxonMobil's stock has increased by 8% this year and is trading at an estimated 16 times its future earnings, presenting a good value for income investors [16]

Core Insights - The article discusses the author's background in analytics and accounting, highlighting over 10 years of experience in the investment sector, progressing from an analyst to a management role [1]. Group 1 - The author holds a master's degree in Analytics from Northwestern University and a bachelor's degree in Accounting [1]. - The author has a personal interest in dividend investing and aims to share insights with the Seeking Alpha community [1]. Group 2 - The author has disclosed a beneficial long position in several companies, including ABBV, ADP, CTAS, FDS, HRL, JNJ, LOW, NEE, O, PEP, TROW, and WST, through various financial instruments [2]. - The article expresses the author's personal opinions and does not involve compensation from any mentioned companies [2].

Buying a dividend stock and forgetting about it isn’t as simple as it sounds, even for seasoned income investors. The market could crash, the income potential might not be worth it, and you might end up thinking that your money is better off somewhere else. That said, the buy-and-forget approach isn’t impossible either. Buy-and-Forget stocks are investors' “core holdings” that they keep forever, regardless of what happens. And today, I came up with three such dividend stocks from the Dividend Kings list t ...

Core Insights - AbbVie has announced two positive updates for Canadians living with ulcerative colitis (UC) [1] - Canada's Drug Agency (CDA-AMC) has recommended SKYRIZI (risankizumab) for reimbursement under specific conditions for adults with moderately to severely active UC [2][3] - AbbVie has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI for UC, resulting in a signed Letter of Intent (LOI) [3][5] Summary by Sections Treatment Recommendations - The CDA-AMC's recommendation for SKYRIZI is based on feedback from 25 Canadian clinicians and two patient organizations, ensuring patient perspectives were included [3] - SKYRIZI is indicated for adults with UC who have had inadequate responses to conventional therapies, biologic treatments, or Janus kinase (JAK) inhibitors [8] Clinical Evidence - The positive recommendations for SKYRIZI were supported by evidence from pivotal phase 3 clinical trials, including MOTIVATE, ADVANCE, FORTIFY (for Crohn's disease), and INSPIRE, COMMAND (for UC) [5] Patient Impact - The introduction of SKYRIZI is seen as a significant step towards providing effective treatment options for UC patients, which can help improve their quality of life and long-term health outcomes [5][6] - Approximately 120,000 Canadians are estimated to live with UC, highlighting the need for effective treatment options [7] Company Commitment - AbbVie expresses commitment to improving patient access to innovative medicines for inflammatory bowel disease through collaboration with health authorities [6]

Core Viewpoint - The article highlights eight dividend stocks that cater to various investment styles, emphasizing the importance of balancing current income with long-term growth in a diversified dividend strategy [1][2]. Group 1: Stock Summaries - **American Express (AXP)**: Operates a closed-loop payments network with a yield of 0.87% and a payout ratio of 16%, indicating significant potential for dividend growth due to its affluent customer base and strong pricing power [3][4]. - **JPMorgan Chase (JPM)**: The largest U.S. bank by assets, offering a 2% yield and a 28% payout ratio, making it a solid choice for investors seeking both income and capital appreciation [5]. - **Costco (COST)**: Generates profit primarily from membership fees, with a low yield of 0.5% but a 27% payout ratio and a history of substantial special dividends, showcasing its commitment to shareholder returns [6][7]. - **S&P Global (SPGI)**: Provides essential financial market services with a yield of 0.8% and a 28% payout ratio, boasting a 52-year history of dividend increases, reflecting its strong market position [9]. - **AbbVie (ABBV)**: A biopharmaceutical company with a 3% yield and a remarkable 53 consecutive years of dividend increases, supported by a robust pipeline and strategic acquisitions [10]. - **Pfizer (PFE)**: A major pharmaceutical company with a high yield of 6.7% but a payout ratio near 98%, appealing to income-focused investors despite earnings volatility risks [11]. - **Philip Morris International (PM)**: Offers a 3.8% yield with a payout ratio of nearly 78%, focusing on smoke-free products to differentiate itself and provide growth opportunities [12][13]. - **Nvidia (NVDA)**: A technology company with a minimal yield of 0.02% but a low payout ratio of 1%, indicating strong potential for future dividend growth driven by substantial free cash flow [15].

Core Insights - Pfizer and AbbVie are both leading U.S. pharmaceutical companies with strong positions in various therapeutic areas, with Pfizer's oncology sales accounting for approximately 28% of its total revenues and AbbVie’s immunology drugs contributing around 50% of its net revenues [1][2]. Pfizer (PFE) Overview - Pfizer has strengthened its oncology position with the acquisition of Seagen in 2023, leading to a 7% increase in oncology revenues year-to-date, driven by key drugs [4]. - Non-COVID operational revenues are improving, with a 9% operational increase in recently launched and acquired products in the first nine months of 2025, supporting growth expectations for 2026 [5]. - Pfizer anticipates cost savings of $7.7 billion by the end of 2027 through restructuring and cost reduction efforts, with a dividend yield of around 7% [6]. - The company is expanding its pipeline through acquisitions, including a $10 billion deal for Metsera, which adds significant potential in the obesity market [7]. - Pfizer faces challenges with declining sales of COVID products and expects a significant impact from patent expirations between 2026-2030, estimating a $1 billion unfavorable impact from the Inflation Reduction Act [8][10]. AbbVie (ABBV) Overview - AbbVie has successfully navigated the loss of exclusivity for Humira by launching new immunology drugs, Skyrizi and Rinvoq, which generated combined sales of $18.5 billion in the first nine months of 2025 [11][12]. - The oncology segment contributed $5.0 billion in revenues, while neuroscience drugs saw a 20.3% increase in sales, totaling almost $7.8 billion [13]. - AbbVie has pursued inorganic growth through over 30 M&A transactions since early 2024, particularly in immunology, while facing near-term challenges from Humira's biosimilars and competitive pressures [14]. - The aesthetics portfolio has seen a 7.4% decline in global sales, impacted by macroeconomic challenges and low consumer sentiment [15]. Financial Estimates and Performance - The Zacks Consensus Estimate for Pfizer's 2025 sales implies a 1.1% decrease, while AbbVie's estimates indicate an 8.1% increase in sales [16]. - Year-to-date, Pfizer's stock has declined by 3.0%, whereas AbbVie's stock has risen by 30.5%, outperforming the industry average of 15.9% [20]. - AbbVie’s dividend yield is 2.8%, compared to Pfizer’s 6.7% [26]. Investment Outlook - Both companies hold a Zacks Rank 3 (Hold), but AbbVie is favored due to its robust growth prospects and lack of significant upcoming loss of exclusivity events [28]. - AbbVie expects to achieve mid-single-digit revenue growth in 2025, driven by the strong performance of Skyrizi and Rinvoq, with a high single-digit CAGR projected through 2029 [29].

Core Insights - AbbVie Inc. is a major player in the pharmaceutical industry with a market cap of $405.6 billion, focusing on various health issues across multiple therapeutic areas [1][2] Company Overview - AbbVie is categorized as a "mega-cap stock" due to its market cap exceeding $200 billion, indicating its substantial size and influence in the drug manufacturing sector [2] - The company has a strong presence in immunology and oncology, with key products like Imbruvica and Rinvoq, supported by significant investments in research and development [2] Stock Performance - AbbVie shares have experienced a decline of 5.3% from their 52-week high of $244.81, reached on October 1 [3] - Over the past three months, AbbVie stock has gained 11.7%, outperforming the Nasdaq Composite's 7.4% increase during the same period [3] - Year-to-date, AbbVie shares have risen by 30.4%, and 30.9% over the past 52 weeks, surpassing the Nasdaq's YTD gains of 19.2% and 20.8% respectively [4] Technical Indicators - AbbVie has been trading above its 200-day moving average since early July, indicating a bullish trend, with some fluctuations [4] - The stock has also been above its 50-day moving average since early June, reflecting a positive trading pattern [4] Growth Drivers - The company's growth is attributed to the success of its products Skyrizi and Rinvoq, along with double-digit growth in neuroscience [5] - AbbVie is making strategic acquisitions, including Gilgamesh and Capstan Therapeutics, and is expanding manufacturing capabilities with a $195 million investment in North Chicago and a $70 million expansion in Worcester [5] - The company is advancing pipeline programs targeting alopecia areata, vitiligo, and Parkinson's disease, despite facing challenges in the aesthetics sector [5] Recent Financial Results - For Q3, AbbVie reported an adjusted EPS of $1.86, exceeding Wall Street's expectation of $1.77, with revenue of $15.8 billion, also above the forecast of $15.6 billion [6] - The company anticipates full-year adjusted EPS in the range of $10.61 to $10.65 [6]

Core Insights - The recent Medicare negotiations are expected to save approximately 36% on the prices of 15 high-cost drugs, translating to around $8.5 billion in net reimbursement costs [1][3][10] - The new prices will take effect in 2027, with significant reductions for popular drugs like semaglutide, which will drop over 70% to about $274 per month [1][4] - The negotiations are part of the Inflation Reduction Act signed by President Biden in 2022, which allows Medicare to negotiate drug prices for the first time [2][11] Drug Price Reductions - The estimated net prices for drugs like Calquence, Ofev, and Ibrance have been reduced by over $4,000 each in the latest negotiations [2][4] - The new pricing for other drugs includes Trelegy Ellipta at $175 (down from $654) and Linzess at $136 (down from $539) [4][10] - The average negotiated prices for these drugs are still higher than those in the Group of Seven (G7) nations, with some drugs costing over $500 more than their G7 counterparts [7][11] Comparison with Previous Negotiations - The 36% savings in the current negotiations surpasses the 22% savings achieved in the previous year's negotiations for 10 different drugs [3][10] - The pricing strategy has become more efficient, with newer products potentially having greater flexibility in pricing [4][10] Industry Response - The pharmaceutical industry has expressed strong opposition to government price negotiations, arguing that such policies are detrimental [5][10] - Industry representatives claim that government pricing policies like the Inflation Reduction Act and the Most-Favored-Nation pricing are misguided [5][12] Future Implications - The Medicare negotiations are expected to influence other payers to seek similar pricing from drug manufacturers [10] - Future negotiations will include an additional 15 drugs, with discussions set to begin in February [12]

Core Viewpoint - The article emphasizes the commitment of AbbVie to participate in the development of the biopharmaceutical ecosystem in Shandong, China, highlighting the importance of international collaboration and innovation in the industry [1][3]. Group 1: Company Strategy - AbbVie views Shandong as a critical strategic hub for its operations in China, having already engaged in over 30 clinical studies with local medical institutions [3]. - The company plans to increase its investment in China, aiming to accelerate global synchronized research and product launches [3]. Group 2: Future Projections - AbbVie anticipates launching more than 40 new products in China by 2030, reflecting its long-term commitment to the Chinese market [3].